From Research at med.fsu.edu Fri Aug 13 16:38:34 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 13 Aug 2021 20:38:34 +0000 Subject: Weekly Funding Opportunities Message-ID: Congressionally Directed Medical Research Programs Traumatic Brain Injury and Psychological Health Research Program Clinical Research Development Award Pre-application (required preproposal): September 8. Full application: September 30. Idea Development Award Pre-application (required preproposal): September 8. Full application: September 30. Investigator Initiated Research Award Pre-application (required preproposal): September 8. Full application: September 30. Med-RA deadline to receive draft documents for full application: September 20. Clinical Trial Award Pre-application (required preproposal): September 15. Invited full application: December 16. Focused Program Award Pre-application (required preproposal): September 15. Invited full application: December 16. Translational Research Award Pre-application (required preproposal): September 15. Invited full application: December 16. Med-RA deadline to receive draft documents for full application: December 6. Sony Research Awards Faculty Innovation Award Global research and development at Sony enables us to foster innovative ideas, which could ultimately lead to future technology advancements and company growth. In order to speed up and expand the creation of new ideas, we would like to partner with universities. This partnership will help cultivate advanced concepts and fertilize our own research and development. The Sony Faculty Innovation Award provides up to $100K USD in funds to conduct pioneering research in the areas of information technology, devices and materials, and biomedical and life science: digital health around respiratory/heart sound analysis; behavioral change interventions / systems / theory in healthcare; MCI and early dementia assistive technology; speech patters / facial expressions / working memory; cognitive ability / social interactions / behavior; remote and telemedicine. $100,000 for one year projects. Focused Research Award Solid research is the underlying driving force to crystallize fearless creativity and innovation. While we are committed to run in-house research and engineering, we are also excited to collaborate with academic partners to facilitate exploration of new and promising research. The Sony Focused Research Award provides an opportunity for university faculty and Sony to conduct this type of collaborative, focused research. The list of candidate research topics includes intelligent sensing of patient reported outcomes. $150,000 for one year projects. Due September 16, 2021. Med-RA deadline to receive draft documents: September 2 (due to Labor Day holiday). Foundation for Opioid Response Efforts: Preventing Opioid Use Disorder and Overdose The Foundation for Opioid Response Efforts (FORE) aims to convene and support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid use disorder (OUD), their families, and their communities. To that end, FORE will provide grant support for specific projects that aim to improve, expand, and/or scale evidence-based family-, school-, and/or community-based prevention services for children and families, particularly for those at highest risk. Applicants may apply for a grant of up to $500,000 per year for up to three years. This RFP targets projects that can develop, adapt, explore, and/or evaluate promising evidence-based models of family- and community-based prevention for OUD and overdose. FORE is particularly interested in taking a holistic approach to the needs of every family member, recognizing that some may be in OUD treatment and/or recovery, while others would benefit from preventive measures. FORE also is interested in community-based intervention approaches that meet children and families where they are, including within schools and ?after school? activities and healthcare settings. Currently, this opportunity will focus on projects in the following three areas which, based on discussions with experts in the field, are needed to improve prevention efforts in communities nationwide: 1. Mitigating the Impact of ACEs on Families: Adverse childhood experiences (ACEs) and trauma play a significant role in whether an individual is susceptible to developing a SUD. People with high ACE scores are more likely to start using drugs or alcohol at an early age and are up to ten times more likely to experience addiction than people who have not experienced childhood trauma. Projects in this focus area include evidence-based prevention models that target children and families at the highest risk, including families who have a caregiver in treatment, recovery, or actively using substances. 2. Developing Models for Racial and Cultural Minorities and Addressing Inequities: In recent years, the gap in the rate of opioid overdoses between racial minorities, such as Black and Latinx individuals and white Americans, has narrowed significantly. The nation?s ?war on drugs? also has led to a disproportionate number of children in these communities growing up without a parent present. Despite the pressing need, the presence of effective interventions in minority communities is limited. Projects in this focus area include developing culturally informed and inclusive prevention models that address health inequities, are effective in diverse communities of color, and identify routes to successful sustainability. 3. Addressing and Managing Pain, Emotional Distress, and Trauma: Alleviating physical and/or emotional pain is a common reason for initiating misuse of opioids and other substances. Projects that help children and adolescents develop healthy ways of responding to pain with interventions or supports that may be based in schools, homes, or communities will be considered. Concept note due September 20, 2021. Med-RA deadline to receive draft documents: September 7. Pfizer: Global Awards for Advancing Chronic Pain Research (ADVANCE) The purpose of this competition is to fund innovative, novel research proposals that seek to advance the understanding and management of chronic pain. Areas of research that are considered in-scope for an ADVANCE research grant, with the condition of interest being osteoarthritis (OA) and chronic pain associated with OA, will include studies that aim to advance the understanding of the following. * Evaluation of unmet medical needs in pain management associated with OA as follows: * Benefit-risk assessment and patient preference in the choice of pain medication for patients with comorbid conditions (e.g., cardiovascular disease or history of substance abuse) * How risks associated with long-term use of analgesics are assessed currently * Treatment of chronic pain in special populations (e.g., postsurgical, elderly) * Evaluation of multi-disciplinary approaches to management of OA (e.g., physical therapy, cognitive behavioral therapy) and their combination with pharmacological treatment * Understand and predict response to treatment, disease state, and course of OA (normal and rapid trajectories) * Approaches to improving adherence to therapy or therapeutic regimes for pain associated with OA * Use of patient characteristics such as biomarkers or other objective evaluations (e.g., quantitative sensory testing , imaging modalities) in the assessment and management of OA to better understand disease course * Evaluation of improved function * How changes of physical function are assessed in clinical practice in patients with OA, and how current physical function assessment could be improved * How individual goal setting can contribute to treatment outcome (including pain and function) * What impact the improved physical function has on the patients? quality of life A total of US $500,000 will be available to fund research proposals of up to US $150,000. Due September 22, 2021. Med-RA deadline to receive draft documents: September 9. Pfizer: Pre-clinical and Translational Research in Multiple Myeloma Grants of up to $150,000 will be awarded in support of pre-clinical and translational research in multiple myeloma. Only pre-clinical projects with a focus on these areas of interest will be considered: correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy; understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment; mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion); correlation between soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity); impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations); mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity; exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) with a focus on drugs that are not currently SOC in myeloma; immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity; and comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab. Studies can be in-vitro or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates). A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies. Due September 28, 2021. Med-RA deadline to receive draft documents: September 15. FSU Office of Commercialization: GAP Commercialization Investment Program Do you have a researcher within your department who has a commercially viable invention? Are you a member of the FSU research community currently working on new innovations that may have value commercially? Would up to $50,000 in funding help you get your idea closer to commercialization of that product or idea? If you answered yes to any of these questions, the FSU GAP Commercialization Investment Program (GAP) may be for you! GAP is a competitive investment program designed to help FSU Researchers move their research towards commercialization. Pre-proposals due September 23, 2021. Med-RA deadline to receive draft documents: September 13. FSU Council on Research and Creativity Committee on Faculty Research Support (COFRS) Program Pre-review deadline: November 8, 2021, 4:59 p.m. Due November 18, 2021. Med-RA deadline to receive draft documents: November 4 (due do Veterans Day holiday). Equipment & Infrastructure Enhancement (EIEG) Program Pre-review deadlines: October 4, 2021, 4:59 p.m. and February 14, 2022 4:59 p.m. Due October 14, 2021 and February 24, 2022. Med-RA deadline to receive draft documents for October 14 deadline: October 4. First Year Assistant Professor (FYAP) Program FYAP Workshop: September 10, 2021 (mandatory for submitters). Pre-review deadline: October 11, 2021, 4:59 p.m. Due October 21, 2021. Med-RA deadline to receive draft documents: October 11. Multidisciplinary Support (MDS) Program Pre-review deadline: January 24, 2021, 4:59 p.m. Due February 3, 2022. Med-RA deadline to receive draft documents: January 24. Planning Grant (PG) Program Pre-review deadlines: September 27, 2021, 4:59 p.m. and February 7, 2022, 4:59 p.m. Due October 7, 2021 and February 17, 2022. Med-RA deadline to receive draft documents for October 7 due date: September 27. Small Grants Program (SGP) Pre-review deadlines: October 4, 2021, 4:59 p.m. and February 28, 2022, 4:59 p.m. Due October 14, 2021 and March 10, 2022. Med-RA deadline to receive draft documents for October 14 due date: October 4. AbbVie: Investigator-initiated studies The purpose of the Investigator-initiated Studies (IIS) Program is to support investigator-initiated research ideas that align with AbbVie?s defined areas of strategic interest (broadly: immunology, oncology, neuroscience, eye care, and aesthetics). The IIS program is not an unrestricted grant program, there are contractual obligations tied to the receipt of any support for an IIS proposal. The research proposal must align with the company?s defined areas of strategic interest. Depending on each therapeutic area?s current interests, this may include: * Investigator-initiated studies involving legacy Allergan and AbbVie products * Non-interventional research, such as epidemiology or outcomes studies, where the focus is on scientific understanding of the disease * In vitro or animal studies Support provided by AbbVie may be in the form of product or funding, dependent on the type of research and availability of funds. Applications accepted on a rolling basis. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Aug 18 13:15:24 2021 From: Research at med.fsu.edu (med-Research) Date: Wed, 18 Aug 2021 17:15:24 +0000 Subject: Weekly funding opportunities In-Reply-To: References: Message-ID: Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. Due September 22, 2021; October 14, 2021; November 9, 2021; December 9, 2021; January 10, 2022; February 10, 2022; March 10, 2022; April 11, 2022; May 10, 2022; June 9, 2022; July 11, 2022; August 9, 2022; September 9, 2022; October 7, 2022; November 9, 2022; December 9, 2022; January 10, 2023; February 9, 2023; March 9, 2023; April 11, 2023; May 9, 2023; June 9, 2023; July 11, 2023; August 9, 2023; September 8, 2023; October 10, 2023; November 9, 2023; December 11, 2023; January 9, 2024; February 9, 2024; March 8, 2024; April 9, 2024; May 8, 2024; June 10, 2024, July 9, 2024; August 9, 2024; and September 10, 2024. Med-RA deadline to receive draft documents for September 22, 2021 due date: September 9. Caplan Foundation for Early Childhood Grants The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through 7 years, in the United States. Welfare is broadly defined to include physical and mental health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare. Grants are only made if a successful project outcome will likely be of significant interest to other professionals, within the grantee?s field of endeavor, and would have a direct benefit and potential national application. The Foundation?s goal is to provide seed money to implement those imaginative proposals that exhibit the greatest chance of improving the lives of young children, on a national scale. Because of the Foundation?s limited funding capability, it seeks to maximize a grant?s potential impact. 1. Early Childhood Welfare: Children can only reach their full potential when all aspects of their development ? intellectual, emotional and physical ? are supported. Providing a safe and nurturing environment for infants and preschoolers is essential, as is imparting to them the skills of living in a culturally diverse world. To that end, the foundation supports programs that research best child-rearing practices and identify models that can provide creative, caring environments in which all can children thrive. 2. Early Childhood Education and Play: Research shows that children need to be stimulated as well as nurtured early in life if they are to succeed in school, work, and life. That preparation relates to every aspect of a child?s development, and everywhere a child learns ? at home, in childcare settings and in preschool. The foundation seeks to improve the quality of both early childhood teaching and learning through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments. 3. Parenting Education: To help parents create nurturing environments for their children, the foundation supports programs that teach parents about developmental psychology, cultural child-rearing differences, pedagogy, issues of health, prenatal care, and diet, as well programs that provide both cognitive and emotional support to parents. Letter of inquiry due September 30, 2021. Med-RA deadline to receive draft documents: September 20. R01: Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology ? to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model?s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ?personalized match? between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. R01: Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. R34: Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of existing family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology ? to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and pilot test the navigator model?s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and pilot test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ?personalized match? between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5. R34: Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (Clinical Trial Required) This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of individuals across the life span. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5. Innovative Mental Health Services Research Not Involving Clinical Trials (R01) The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: 1. Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; 2. Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; 3. Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; 4. Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals. Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22. Dementia Care and Caregiver Support (R61 / R33 and R01) R61 / R33: Pragmatic Trials for Dementia Care and Caregiver Support (Clinical Trial Required) This Funding Opportunity Announcement will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer?s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care. R01: Dementia Care and Caregiver Support Intervention Research (Clinical Trial Required) This Funding Opportunity Announcement solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer?s disease (AD) and Alzheimer?s disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention?s principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions. The principle-based interventions under development may target behavioral, psychological, interpersonal, social, or institutional processes and may be designed for use at the individual, family, dyad, group, community, or health-systems level. Applications may propose mechanism-focused intervention research for individuals living with dementia or for individuals or systems providing care for people at any stage of AD/ADRD. Applications proposing the development of interventions that address the principles underlying the care needs and challenges for individuals from diverse racial, ethnic, and socioeconomic backgrounds are strongly encouraged. Applications that involve interdisciplinary expertise and translational expertise (e.g., basic behavioral, social, psychological, or neurobiological science expertise relevant to hypothesized intervention mechanisms; expertise in the AD/ADRD service delivery system; and clinical psychological science expertise in areas outside of aging or AD/ADRD, but potentially relevant to AD/ADRD caregiver research, etc.) are also strongly encouraged. Applications may propose to create, modify, and test AD/ADRD care and caregiver support interventions based upon hypothesized mechanisms of action and are encouraged to incorporate a test of essential components or mechanisms of change using an appropriate methodological approach. Due October 7, 2021; February 10, 2022; October 11, 2022; February 10, 2023; October 10, 2023; and February 13, 2024. Med-RA deadline to receive draft documents for October 7, 2021 due date: September 27. Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson?s Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly shareable through the PDBP repositories. Due October 22, 2021. Med-RA deadline to receive draft documents: October 11. Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed) Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD and have been significantly less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field and to support further work in this area through investigator-initiated and other mechanisms. Due October 22, 2021. Med-RA deadline to receive draft documents: October 11. Florida Medical Malpractice Joint Underwriting Association Grants for Partnerships in Improving the Safety of Health Care Services: The Alvin E. Smith Safety of Health Care Services Grant Program The purpose of this RFA is to support projects that are intended to (1) identify, develop, test, and implement safe practice initiatives in inpatient and/or outpatient settings; and (2) share the findings and lessons learned including the challenges and barriers to developing and implementing these interventions through validated tools, products, and/or health care safety toolkits. The interventions and any resulting implementation toolkits shall be made publicly available so that they may be adapted and/or adopted by other health care organizations. Due November 8, 2021. Med-RA deadline to receive draft documents: October 26. Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy (R01 Clinical Trial Not Allowed) This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy). Investigations should be based on existing, well-characterized populations of patients with a history of TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data and to create a data and associated biofluid resource for the broader community to further advance research in this area. Due November 10, 2021. Med-RA deadline to receive draft documents: October 28. Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3 / UH3 Clinical Trial Optional) The purpose of this UG3/UH3 Phased Innovation Award Funding Opportunity Announcement is to support research to understand and respond to the new challenges in treating drug addiction and overdose, introduced by the presence of fentanyl and its analogs (fentanyls) in illicit drug supplies. Applications should focus on understanding and treating opioid and polydrug use disorders (including overdose), wherein fentanyls are a major contributor and their presence has altered previous estimations of the scope, impact and treatment of the problem. The research may include preclinical, clinical, epidemiological or even post-mortem studies. Studies should have high significance in order to quickly yield improvements in understanding and to provide effective responses to the problems caused by illicit fentanyls. Responsive studies might focus on how fentanyls are complicating treatment of opioid or poly-drug addiction / overdose and might establish underlying mechanisms. Studies might also design / test novel or revised mechanism-based treatment strategies based on differences in pharmacological responses to fentanyls compared with semisynthetic opiates. Studies aimed at developing new or repurposed medications or therapeutic devices should aim to significantly advance the program towards FDA approval. Responsive studies may also require the development and implementation of improved sampling and analytical techniques to qualitatively and quantitatively evaluate clinical and postmortem toxicological samples. The aims of such analyses would include improving clinical treatment and understanding the public health consequences of fentanyls addiction and overdose. Due November 11, 2021. Med-RA deadline to receive draft documents: November 1. American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) will support research that combines epidemiologic methods, digital technology, and data science approaches to better understand HIV prevention, transmission, and early care-cascade points for women living in the US. Applications must: 1) determine the best ways to identify, enroll, and retain cohorts of women living in the United States (US) who are behaviorally vulnerable to HIV; and 2) develop a knowledgebase comprised of cohort data from women augmented with other data sources including big data sources. Findings should not only lead to a better understanding of how women remain vulnerable to HIV but also inform future pilot interventions aimed at decreasing the incidence of HIV and other sexually transmitted infections (STIs) among cisgender, transgender, and gender non-conforming women. Due December 9, 2021. Med-RA deadline to receive draft documents: November 29. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: